Arovella doses first patient with ALA-101
in first-in-human phase 1 clinical trial
Re-engineering cell therapy with invariant Natural Killer T (iNKT) cells
An allogeneic, off‑the‑shelf CAR‑iNKT platform now entering first‑in‑human trials in Australia.
OUR PLATFORM
We engineer invariant Natural Killer T (iNKT) cells to deliver a multi-pronged attack against cancer. CAR-iNKT cells have multiple ways to kill cancer cells.
Engineered targeting via the CAR
Natural targeting via the invariant TCR / CD1d axis and NKG2D pathway
Remodulate the tumour microenvironment
Activate T and NK cells
Learn more about our science →
Watch the video below to learn how CAR-iNKT cells work.
OUR PROGRAMS
ALA-101 | Allogeneic CD19-directed CAR-iNKT cells
Targets CD19-positive B cell lymphomas and leukaemias
IND Approved, Ethics Approved, Phase I study initiated in Australia
Due to commence first patient dosing in Q3 CY2026
ALA-105 | Allogeneic CLDN18.2-directed CAR-iNKT cells with IL-12-TM cytokine armouring
Targets CLDN18.2-positive gastric and pancreatic cancers
Utilises novel, proprietary CLDN18.2-targeting CAR and membrane-anchored IL-12 cytokine armouring
Armouring improves cell persistence and durability of the anti-tumour response under high tumour burden
ALA-101-001 CLINICAL TRIAL
An open label, phase 1 dose escalation and expansion trial evaluating the safety, tolerability and preliminary efficacy of ALA-101 in patients with relapsed or refractory lymphomas and leukaemias.
“Dosing the first patient with ALA-101 is a key milestone in the development of a new class of cell therapies for patients with relapsed or refractory B cell malignancies. Despite advances in treatment, many patients either relapse following standard therapies or are unable to access currently available autologous CAR-T therapies. We look forward to evaluating the safety and potential clinical activity of ALA-101 and contributing to the advancement of this novel allogeneic CAR-iNKT cell approach.”
To learn more about our trial, please contact us.
